Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans
| Autor: | Joan Dragavon, Robert W. Coombs, R. Ashley Morrow, F. Kambugu, Edith Nakku-Joloba, David Friedrich, Connie Celum, Amalia Magaret, Jairam R. Lingappa, Christopher C. Whalen, Moses Joloba |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Sexually transmitted disease Herpesvirus 2 Human viruses Population HIV Infections Dermatology Antibodies Viral Sensitivity and Specificity Article Serology Blood serum Virology Humans Medicine Uganda Pharmacology (medical) education Sida Immunoassay education.field_of_study medicine.diagnostic_test biology business.industry Public Health Environmental and Occupational Health virus diseases Herpes Simplex biology.organism_classification Infectious Diseases Immunology Female Reagent Kits Diagnostic Viral disease business Serostatus |
| Zdroj: | International Journal of STD & AIDS. 21:611-616 |
| ISSN: | 1758-1052 0956-4624 |
| Popis: | Background—Herpes Simplex Virus-2 (HSV-2) is a risk factor for HIV-1 infection; HSV-2 serology may be useful for HIV-1 prevention. We characterized HSV-2 serology assay performance in HIV-positive and HIV-negative Africans. Methods—Serostatus for HSV-2 and HIV-1 was determined in 493 serum specimens stored from a community HSV-2 prevalence survey in Kampala, Uganda. HSV-2 serology by Focus HerpeSelect ELISA, Biokit HSV-2 rapid assay, and Kalon HSV-2 were compared to Western Blot (WB) by HIV-1 serostatus. Results—Sensitivity/specificity were: 99.5%/70.2% for Focus, 97.0%/86.4% for Biokit, and 97.5%/96.2% for Kalon. Focus with Biokit confirmation improved sensitivity/specificity (99.4%/ 96.8%, respectively). Use of a higher Focus index value cutoff of 2.2 instead of 1.1 increased specificity from 70.2% to 92.4%. Kalon had higher specificity than Focus (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|